Tag: Mu-opioid antagonist (short-acting)

  • Naloxone

    Mu-opioid antagonist (short-acting)

    A short-acting mu-opioid antagonist; the standard reversal agent for opioid overdose.

    Abstract

    Naloxone ((5alpha)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; CAS 465-65-6; molecular formula C19H21NO4; molecular weight 327.37) is a short-acting mu-opioid antagonist approved by the FDA in 1971 (Narcan). The compound is a competitive antagonist at mu, kappa, and delta opioid receptors with preferential mu affinity (Ki approximately 1 nM). Unlike naltrexone, oral bioavailability is poor (less than 5 percent), restricting use to parenteral or intranasal administration. Plasma half-life is approximately 1 to 2 hours, shorter than most opioid agonists, requiring multiple doses or infusion in opioid overdose reversal where the half-life of the offending opioid exceeds naloxone’s. Approved indications: opioid overdose reversal, postoperative opioid reversal, opioid-induced constipation (IV form alvimopan, methylnaltrexone for that latter). Used as the canonical mu-opioid antagonist in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.